The multiple mechanisms and therapeutic significance of rutin in metabolic dysfunction-associated fatty liver disease (MAFLD)

被引:0
|
作者
Wang, Qianzhuo [1 ]
Zhang, Yingjuan [2 ]
Lu, Ruiling [1 ]
Zhao, Qingwen [2 ]
Gao, Yue [2 ]
机构
[1] Zhejiang Chinese Med Univ, Sch Clin Med 4, Hangzhou 310053, Zhejiang, Peoples R China
[2] Westlake Univ, Affiliated Hangzhou Peoples Hosp 1, Sch Med, Zhejiang Key Lab Tradit Chinese Med Prevent & Trea, Hangzhou 310006, Zhejiang, Peoples R China
关键词
Rutin; Metabolic dysfunction-associated fatty liver; disease; Signaling pathway; Therapy; ANTIOXIDANT PROPERTIES; DOUBLE-BLIND; OBESITY;
D O I
10.1016/j.fitote.2024.106178
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The global incidence of metabolic dysfunction-associated fatty liver disease (MAFLD) has been steadily increasing, making it a leading chronic liver disease. MAFLD refers to a metabolic syndrome linked with type 2 diabetes mellitus, obesity. However, its pathophysiology is complex, there are currently no effective and approved medicines for therapy. Rutin, a naturally occurring polyphenolic flavonoid, is widely distributed in fruits, vegetables, and other plants. It exhibits a plethora of bioactive properties, such as antioxidant, anticancer, and anti-inflammatory and neuroprotective activities, making it an extremely promising phytochemical. Rutin has shown great potential in the treatment of a wide variety of metabolic diseases and received considerable attention in recent years. Fortuitously, various research studies have validated rutin's extensive biological functions in treating metabolic disorders. Despite the fact that the exact pathophysiological mechanisms through which rutin has a hepatoprotective effect on MAFLD are still not fully elucidated. This review comprehensively outlines rutin's multifaceted preventive and therapeutic effects in MAFLD, including the modulation of lipid metabolism, reduction of insulin resistance, diminution of inflammation and oxidative stress, combatting of obesity, and influence on intestinal flora. This paper details the known molecular targets and pathways of rutin in MAFLD pathogenesis. It endeavored to provide new ideas for treating MAFLD and accelerating its translation from bench to bedside.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] Association of metabolic dysfunction-associated fatty liver disease with kidney disease
    Wang, Ting-Yao
    Wang, Rui-Fang
    Bu, Zhi-Ying
    Targher, Giovanni
    Byrne, Christopher D.
    Sun, Dan-Qin
    Zheng, Ming-Hua
    [J]. NATURE REVIEWS NEPHROLOGY, 2022, 18 (04) : 259 - 268
  • [42] METABOLIC DYSFUNCTION-ASSOCIATED FATTY LIVER DISEASE (MAFLD) PREDICTS NEW ONSET OF CHRONIC KIDNEY DISEASE BETTER THAN DOES FATTY LIVER OR NAFLD
    Tanaka, Marenao
    Mori, Kazuma
    Takahashi, Satoko
    Higashiura, Yukimura
    Ohnishi, Hirofumi
    Hanawa, Nagisa
    Furuhashi, Masato
    [J]. JOURNAL OF HYPERTENSION, 2023, 41 : E333 - E334
  • [43] Mitochondrial Dysfunction in Metabolic Dysfunction Fatty Liver Disease (MAFLD)
    Zhao, Ying
    Zhou, Yanni
    Wang, Dan
    Huang, Ziwei
    Xiao, Xiong
    Zheng, Qing
    Li, Shengfu
    Long, Dan
    Feng, Li
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (24)
  • [44] Validation of fatty liver index as a marker for metabolic dysfunction-associated fatty liver disease
    Han, A. Lum
    [J]. DIABETOLOGY & METABOLIC SYNDROME, 2022, 14 (01):
  • [45] Validation of fatty liver index as a marker for metabolic dysfunction-associated fatty liver disease
    A Lum Han
    [J]. Diabetology & Metabolic Syndrome, 14
  • [46] Excess Body Weight and Metabolic (Dysfunction)-Associated Fatty Liver Disease (MAFLD)
    Roeb, Elke
    [J]. VISCERAL MEDICINE, 2021, 37 (04) : 273 - 280
  • [47] Links between metabolic syndrome and metabolic dysfunction-associated fatty liver disease
    Lim, Soo
    Kim, Jin-Wook
    Targher, Giovanni
    [J]. TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2021, 32 (07): : 500 - 514
  • [48] Skipping breakfast is associated with an increased long-term cardiovascular mortality in metabolic dysfunction-associated fatty liver disease (MAFLD) but not MAFLD-free individuals
    Xie, Jiarong
    Huang, Hangkai
    Chen, Yishu
    Xu, Lei
    Xu, Chengfu
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022, 55 (02) : 212 - 224
  • [49] Metabolic dysfunction-associated fatty liver disease (MAFLD) and advanced liver fibrosis among hemodialysis patients in a multiethnic urban population in Malaysia
    Wong, Wei-Kei
    Chan, Wah-Kheong
    Ganapathy, Shubash Shander
    Lim, Soo-Kun
    [J]. SEMINARS IN DIALYSIS, 2023, 36 (02) : 107 - 116
  • [50] Are dairy products the answer to metabolic dysfunction-associated fatty liver disease?
    Lau, Kristopher Cho-Hei
    Wong, Vincent Wai-Sun
    [J]. HEPATOLOGY INTERNATIONAL, 2024, 18 (03) : 870 - 872